Actos (MDL 2299) Lawsuit Update: Jury Selection Completed for First Actos Bladder Cancer Trial in Federal Court
The first bellwether trial in the Multidistrict Litigation In re: Actos® (Pioglitazone) Products Liability Litigation, MDL 2299, began on January 27, 2014 with jury selection. Now that the jury has been selected, and after pretrial matters are addressed, testimony is set to begin on February 3 with the trial expected to last approximately six weeks. The first bellwether case in the MDL involves plaintiff Terrence Allen and his wife. Mr. Allen took Actos® for nearly 7 years as treatment for his Type 2 diabetes. In 2011, he was diagnosed with bladder cancer, allegedly caused by Actos®.
Actos® is a medication prescribed to control glucose (blood sugar) in adults with Type 2 diabetes. The Food and Drug Administration (“FDA”) approved Actos® in 1999. The drug subsequently became the world’s best-selling diabetes treatment with Actos® sales peaking between March 2010 and March 2011 at $4.5 billion, or 27 percent of Takeda revenue, according to data compiled by Bloomberg News. In June 2011, the FDA issued a Drug Safety Alert warning that the use of Actos® for more than one year may be associated with an increased risk of bladder cancer. Two research studies provide support for a link between Actos® and bladder cancer. In May 2012, the British Medical Journal published a study concluding that patients using Actos® were twice as likely to develop bladder cancer after taking the medication for two years. In August 2012, another article published in the Canadian Medical Association Journal concluded that patients taking Actos® were 22% more likely to develop bladder cancer.
The Actos® Multidistrict Litigation (MDL 2299) is currently pending in the United States District Court for the Western District of Louisiana before The Honorable Judge Rebecca F. Doherty. According to the most recent report issued by the Judicial Panel on Multidistrict Litigation, there are nearly 2,700 cases currently on file against Takeda Pharmaceuticals, the manufacturer of the diabetes drug Actos®, in MDL 2299.
Schlichter, Bogard & Denton, LLP is a law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries. If you or a loved one developed bladder cancer after taking Actos® for more than one year, please contact Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
The choice of a lawyer is an important decision and should not be based solely on advertisements. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.